One Genomics, an AI-driven genomics company focused on advancing de-aging science, has announced a strategic research collaboration with the CiRA Foundation, a leading induced pluripotent stem (iPS) cell manufacturing and research organization based in Kyoto, Japan. The partnership aims to push the boundaries of precision genome engineering by combining One Genomics’ advanced AI-powered CRISPR design platform with CiRA Foundation’s world-class expertise in iPS cell technology. Despite significant progress in genome editing, conventional methods—particularly CRISPR-based systems—still face major limitations. These include off-target mutations, bystander effects, and an inability to precisely control editing outcomes. Such challenges hinder the safety, reliability, and clinical applicability of genome engineering, especially in human cells, creating a critical bottleneck for regenerative medicine and advanced therapies. Under the collaboration, One Genomics will provide its proprietary high-precision, fine-tunable CRISPR platform, including its patented “Safeguard” technology, designed to minimize unintended edits and enhance control over genetic modifications. The CiRA Foundation will apply these tools in human iPS cells, leveraging its extensive experience in stem cell manufacturing, quality assurance, and regenerative medicine research to validate and optimize performance across biologically relevant cellular contexts. The joint effort seeks to develop next-generation genome engineering technologies that offer greater accuracy, controllability, and reproducibility—essential qualities for both research and future clinical applications. This includes advancing cellular reprogramming for aging reversal, disease modeling, and genetic correction. One Genomics was co-founded by Diana Luan, an MIT-trained AI entrepreneur; George Church, Ph.D., professor at Harvard Medical School and a pioneering geneticist; and former Harvard research fellows Masaki Kawamata, Ph.D., and Motoshi Hayano, Ph.D. The company is building foundational technologies for cellular reprogramming with the long-term vision of making aging optional. It combines AI-driven virtual cell models that simulate aging and recovery processes with precision genome engineering tools to programmatically influence cell state. The CiRA Foundation, established in 2020 as an offshoot of Kyoto University’s Center for iPS Cell Research and Application (CiRA), is dedicated to making high-quality iPS cell technologies accessible and affordable. It specializes in large-scale iPS cell manufacturing, rigorous quality control, long-term storage, and the automation of production processes—key steps toward realizing the promise of regenerative medicine. Through this partnership, both organizations aim to accelerate innovation in precision genomics, bringing transformative advances closer to clinical reality.